Rotavirus vaccine and intussusception: Where do we go from here?

Infectious Disease Clinics of North America

Volumn 15, Issue 1, 2001, Pages 189-207

  Dennehy, Penelope H ^a   Bresee, Joseph S ^b  

^a RHODE ISLAND HOSPITAL   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ROTAVIRUS VACCINE;

CLINICAL FEATURE; DIARRHEA; DRUG SAFETY; HUMAN; INFECTION PREVENTION; INTUSSUSCEPTION; POSTMARKETING SURVEILLANCE; REVIEW; RISK ASSESSMENT; ROTAVIRUS; VACCINATION; VIRUS INFECTION;

EID: 0035062526     PISSN: 08915520     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0891-5520(05)70275-0     Document Type: Article

References (86)

1. Prevention of rotavirus disease: Guidelines for use of rotavirus vaccine
2. Phase 1 trial of a candidate rotavirus vaccine (RV3) derived from a human neonate
3. Evaluation of rhesus rotavirus monovalent and tetravalent reassortant vaccines in US children. US Rotavirus Vaccine Efficacy Group
4. Efficacy of live, attenuated, human rotavirus vaccine 89-12 in infants: A randomised placebo-controlled trial
5. Evaluation of WC3 rotavirus vaccine and correlates of protection in healthy infants
6. Safety and immunogenicity of live, attenuated human rotavirus vaccine 89-12
7. Clinical immunity after neonatal rotavirus infection. A prospective longitudinal study in young children
8. Pediatric viral gastroenteritis during eight years of study
9. Current status and future priorities for rotavirus vaccine development, evaluation and implementation in developing countries
10. Prevalence of rotavirus on high-risk fomites in day-care facilities
11. Fatal rotavirus gastroenteritis: An analysis of 21 cases
12. Intussusception among recipients of rotavirus vaccine - United States, 1998-1999
13. Rotavirus vaccine for the prevention of rotavirus gastroenteritis among children. Recommendations of the Advisory Committee on Immunization Practices (ACIP)
14. Withdrawal of rotavirus vaccine recommendation
15. Field trial of rhesus rotavirus vaccine in infants
16. Protective effect of WC3 vaccine against rotavirus diarrhea in infants during a predominantly serotype 1 rotavirus season
17. The development of multivalent bovine rotavirus (strain WC3) reassortant vaccine for infants
18. WC3 reassortant vaccines in children
19. Preliminary evaluation of the safety and efficacy of quadrivalent human-bovine rotavirus vaccine
20. Safety and immunogenicity of live attenuated human-bovine (UK) reassortant rotavirus vaccines with VP7-specificity for serotypes 1, 2, 3 or 4 in adults, children and infants
21. New vaccines against mucosal pathogens: Rotavirus and respiratory syncytial virus
22. Role of coproantibody in clinical protection of children during reinfection with rotavirus
23. Risk of diarrhea during the first year of life associated with initial and subsequent colonization by specific enteropathogens
24. Epidemiology of rotavirus diarrhoea in Africa: A review to assess the need for rotavirus immunization
25. Interventions for the control of diarrhoeal diseases among young children: Rotavirus and cholera immunizations
26. Failure of live, attenuated oral rotavirus vaccine
27. Rotavirus gene structure and function
28. Review of G and P typing results from a global collection of rotavirus strains: Implications for vaccine development
29. Evaluation of the efficacy of a low-passage bovine rotavirus
30. The epidemiology of rotavirus diarrhea in the United States: Surveillance and estimates of disease burden
31. Prolonged efficacy of rhesus rotavirus vaccine in Swedish children
32. Homotypic and heterotypic epitope-specific antibody responses in adult and infant rotavirus vaccinees: Implications for vaccine development
33. Diarrhea among infants and young children in Canada: A longitudinal study in three northern communities
34. Trial of an attenuated bovine rotavirus vaccine (RIT 4237) in Gambian infants
35. Etiology of acute diarrhoea among children in developing countries: A multicentre study in five countries
36. The prospects for immunizing against rotavirus
37. Randomised placebo-controlled trial of rhesus-human reassortant rotavirus vaccine for prevention of severe rotavirus gastroenteritis
38. Prolonged efficacy of rhesus-human reassortant rotavirus vaccine
39. Symptoms associated with rhesus-human reassortant rotavirus vaccine in infants
40. Efficacy of a quadrivalent rhesus rotavirus-based human rotavirus vaccine aimed at preventing severe rotavirus diarrhea in infants and young children
41. Trends of diarrheal disease-associated mortality in US children, 1968 through 1991
42. Human rotavirus infection in infants and young children with intussusception
43. Patterns and etiology of diarrhea in three clinical settings
44. Protection of Peruvian children against rotavirus diarrhea of specific serotypes by one, two, or three doses of the RIT 4237 attenuated bovine rotavirus vaccine
45. Safety, immunogenicity, and protective efficacy of one and three doses of the tetravalent rhesus rotavirus vaccine in infants in Lima, Peru
46. Immunogenicity, safety and efficacy of tetravalent rhesus-human, reassortant rotavirus vaccine in Belem, Brazil
47. Reappraisal of the Peruvian and Brazilian lower titer tetravalent rhesus-human reassortant rotavirus vaccine efficacy trials: Analysis by severity of diarrhea
48. Field trial of rhesus rotavirus or human-rhesus rotavirus reassortant vaccine of VP7 serotype 3 or 1 specificity in infants. The Elmwood, Panorama, and Westfall Pediatric Groups
49. Impact of rotavirus infection at a large pediatric hospital
50. Fecal antibody responses to symptomatic and asymptomatic rotavirus infections
51. Reassortment rotavirus as potential live rotavirus vaccine candidates
52. Single gene substitution rotavirus reassortants containing the major neutralization protein (VP7) of human rotavirus serotype 4
53. Rotavirus vaccines: An overview
54. A two-part study of the aetiological role of rotavirus in intussusception
55. Rotavirus Vaccine Field Investigation Team: Multi-state investigation of possible association between tetravalent Rhesus-based rotavirus vaccine (RRV-TV) and intussusception
56. A one-year virological survey of acute intussusception in childhood
57. Epidemiology of diarrheal disease among children enrolled in four West Coast health maintenance organizations
58. Hospitalizations associated with rotavirus diarrhea in the United States, 1993 through 1995: Surveillance based on the new ICD-9-CM rotavirus-specific diagnostic code
59. The impact of rotavirus disease in Venezuela
60. Prospective study of diarrheal diseases in Venezuelan children to evaluate the efficacy of rhesus rotavirus vaccine
61. Efficacy of the rhesus rotavirus-based quadrivalent vaccine in infants and young children in Venezuela
62. Detection and characterization of novel rotavirus strains in the United States
63. The effects of host age, virus dose, and virus strain on heterologous rotavirus infection of suckling mice
64. Safety and efficacy of high-dose rhesus-human reassortant rotavirus vaccines - Report of the National Multicenter Trial
65. Preliminary evaluation of the efficacy of rhesus rotavirus vaccine strain MMU 18006 in young children
66. An efficacy trial of the rhesus rotavirus vaccine in Maryland
67. Lack of an apparent association between intussusception and wild or vaccine rotavirus infection
68. An observational study of naturally acquired immunity to rotaviral diarrhea in a cohort of 363 Egyptian children. Calculation of risk for second episodes using age-specific person-years of observation
69. Longitudinal study of rotavirus infection and gastroenteritis in families served by a pediatric medical practice: Clinical and epidemiologic observations
70. The reporting sensitivities of two passive surveillance systems for vaccine adverse events
71. A field study of the safety and efficacy of two candidate rotavirus vaccines in a Native American population
72. Efficacy and safety of high-dose rhesus-human reassortant rotavirus vaccine in Native American populations
73. Epidemiology of rotavirus diarrhea in a prospectively monitored American Indian population
74. Diarrhoeal disease: Current concepts and future challenges. Epidemiology of diarrhoeal diseases in developed countries
75. Padiatric intussusception
76. Cost-effectiveness analysis of a rotavirus immunization program for the United States
77. Extramucosal spread and development of hepatitis in immunodeficient and normal mice infected with rhesus rotavirus
78. Rotavirus infections in infants as protection against subsequent infections
79. Protection of infants against rotavirus diarrhoea by RIT 4237 attenuated bovine rotavirus strain vaccine
80. Clinical efficacy of the RIT 4237 live attenuated bovine rotavirus vaccine in infants vaccinated before a rotavirus epidemic
81. Review of rotavirus vaccine trials in Finland
82. Rhesus Rotavirus candidate vaccine. Clinical trial in children vaccinated between 2 and 5 months of age
83. Efficacy of two doses of RIT 4237 bovine rotavirus vaccine for prevention of rotavirus diarrhoea
84. Mechanisms of protection against rotavirus in humans and mice
85. Shedding of rotavirus after administration of the tetravalent rhesus rotavirus vaccine
86. Rotaviral immunity in gnotobiotic calves: Heterologous resistance to human virus induced by bovine virus